LLY
Eli Lilly and Company
- Capital expenditures, 2025
- $7.8B
- YoY, 2025
- +55.0%
- 5-year CAGR
- +41.4%
- 10-year CAGR
- +22.1%
Capital expenditures
Capital expenditures by fiscal year
| Period | Capex | YoY |
|---|---|---|
| 2025 | $7.8B | +55.0% |
| 2024 | $5.1B | +46.7% |
| 2023 | $3.4B | +85.9% |
| 2022 | $1.9B | +41.6% |
| 2021 | $1.3B | −5.6% |
| 2020 | $1.4B | +34.2% |
| 2019 | $1.0B | −14.6% |
| 2018 | $1.2B | +12.4% |
| 2017 | $1.1B | +3.8% |
| 2016 | $1.0B | −2.7% |
| 2015 | $1.1B | −8.3% |
| 2014 | $1.2B | +14.9% |
| 2013 | $1.0B | +11.8% |
| 2012 | $905M | +34.7% |
| 2011 | $672M | −3.2% |
| 2010 | $694M | −9.2% |
| 2009 | $765M | −19.2% |
| 2008 | $947M | −12.5% |
| 2007 | $1.1B | — |